Biocon Limited (NSE: BIOCON)
India
· Delayed Price · Currency is INR | Market Cap | 447.25B |
| Revenue (ttm) | 147.66B |
| Net Income (ttm) | 15.81B |
| Shares Out | 1.20B |
| EPS (ttm) | 13.19 |
| PE Ratio | 28.33 |
| Forward PE | 55.69 |
| Dividend | 0.50 (0.13%) |
| Ex-Dividend Date | Jul 5, 2024 |
| Volume | 7,026,619 |
| Open | 383.70 |
| Previous Close | 382.85 |
| Day's Range | 369.05 - 385.90 |
| 52-Week Range | 217.50 - 394.70 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 8, 2024 |
About Biocon
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psor... [Read more]
Financial Performance
In 2023, Biocon's revenue was 147.56 billion, an increase of 32.05% compared to the previous year's 111.74 billion. Earnings were 10.23 billion, an increase of 120.99%.
Financial StatementsNews
Stocks to watch: Maruti, TVS Motors, Emami, NBCC, Biocon, Eicher Motors in focus today (Sept 2, 2024)
The Indian stock market is poised for an eventful day as several companies make headlines with significant developments. From sales figures to acquisitions and regulatory changes, here’s a quick rundo...
Biocon unit gets FDA nod for generic drug
Biocon's subsidiary has been granted approval by the US health regulator to market a generic medication for chronic heart failure treatment.
Want B’luru to be safest city in India: Mazumdar-Shaw
Bengaluru: Batting for safe cities, Kiran Mazumdar-Shaw, executive chairperson and founder of Biocon Ltd, on Saturday said safety of citizens, especia.
CEO of India's Biocon discusses first-quarter results
Peter Bains, group CEO of the biopharmaceutical company, outlines its growth outlook.
Biocon Q1 profit up 6x at 660 crore
India Business News: NEW DELHI: Biotechnology firm Biocon on Thursday said its consolidated profit after tax rose over six-fold to Rs 660 crore in the first quarter ended .
Biocon Q1 profit up 6x at 660cr
Read about Biocon's remarkable six-fold increase in Q1 profit to Rs 660 crore. Discover the reasons behind this significant growth and its impact on the biotechnology industry.